Recombinant Tumor Suppressor ARF (CDKN2A) (full length) anticorps

N° du produit ABIN7879269

L’anticorps anti-Tumor Suppressor ARF Monoclonal Lapin est utilisé pour la détection de Tumor Suppressor ARF dans des échantillons de Humain. Il a été validé pour IHC (p).

Aperçu rapide pour Recombinant Tumor Suppressor ARF (CDKN2A) (full length) anticorps (ABIN7879269)

Antigène: Tumor Suppressor ARF (CDKN2A)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Inconjugué

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: CDKN2A-8196R

Détail du produit

Épitope: full length

Fonction: P16INK4a Antibody / Cyclin-dependent kinase inhibitor 2A Antibody / CDKN2A

Purification: Protein A/G affinity

Immunogène: Purified recombinant prokaryotic full-length human protein was used as the immunogen for the P16INK4a antibody.

Isotype: IgG, kappa

Information d'application

Indications d'application: Optimal dilution of the P16INK4a antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Aliquot the P16INK4a antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détail du antigène

Antigène: Tumor Suppressor ARF (CDKN2A)

Autre désignation: P16INK4a / Cyclin-dependent kinase inhibitor 2A

Sujet: P16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype.

UniProt: P42771